Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 6/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.65 |
| ▸ | BRD4 | O60885 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | SLC40A1 | Q9NP59 | 5/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.63 |
| ▸ | RELA | Q04206 | 1/20 | 0.63 |
| ▸ | MMP2 | P08253 | 1/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22234047 | 1.00 | GAA (0.71) | GAAALDH1A1POLBMEN1KMT2A | |
| SCHEMBL30009657 | 0.92 | GAA (0.73) | GAAALDH1A1POLBMEN1KMT2A | |
| SCHEMBL28389279 | 0.92 | GAA (0.73) | GAAALDH1A1POLBMEN1KMT2A | |
| SCHEMBL22252009 | 0.91 | GAA (0.60) | GAAALDH1A1POLBMEN1KMT2A | |
| SCHEMBL1507919 | 0.86 | SLC40A1 (0.76) | GAAALDH1A1POLBMEN1KMT2A | |
| SCHEMBL30854809 | 0.86 | SLC40A1 (0.76) | GAAALDH1A1POLBMEN1KMT2A | |
| SCHEMBL30854810 | 0.85 | MEN1 (0.67) | GAAALDH1A1POLBMEN1KMT2A | |
| SCHEMBL29255669 | 0.85 | MEN1 (0.67) | GAAALDH1A1POLBMEN1KMT2A | |
| SCHEMBL6981201 | 0.84 | SLC40A1 (0.73) | GAAMEN1KMT2AATMSLC40A1 | |
| SCHEMBL3984153 | 0.84 | MMP2 (0.65) | GAAALDH1A1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12122742-B2 | Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-10-22 | — | — | US | disclosed |
| US-20220112160-A1 | SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112160-A1 | SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | KEAP1, NFE2L2, HMOX1 | GAA 1355/4885ALDH1A1 1856/4885POLB 3248/4885 |
| US-12122742-B2 | Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | GAA 1355/4885ALDH1A1 1856/4885POLB 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.